Zortix
Sign in
What the podcasts are saying about
MRK
In-depth coverage
4
Mentions · 7d
7
Mentions · 30d
7
Mentions · 90d
6
Episodes
Latest attributed ideas · most recent first
18 JULTHE ACQUIRERS PODCAST · 10:50
Hated healthcare names offer defensive value
“The guest argued that select large-cap healthcare and pharmaceutical companies are deeply mispriced due to temporary patent cliffs and political overhangs, offering strong cash flows and high dividend yields.”
In depth · 4/5Verify in source →
17 JULTHE COMPOUND AND FRIENDS · 03:15
The rise of the HALO stock factor
“The post-AI era has birthed a new investment factor called HALO (Heavy Assets, Low Obsolescence), where investors are rotating into businesses that cannot be disrupted by Large Language Models.”
Core thesis · 5/5Verify in source →
17 JULTHE COMPOUND AND FRIENDS · 07:10
Private collective action protects corporate interests
“The guest argued that the most effective way for corporate leaders to counter political pressure from the Trump administration is through private, collective industry action rather than public grandstanding or individual compliance.”
In depth · 4/5Verify in source →
16 JULWSJ WHAT'S NEWS · 06:30
Merck's new cholesterol pill targets blockbuster status
“The FDA approval of Merck's novel cholesterol drug, Lipfendra, positions the company to capture a significant market share in cardiovascular treatment.”
Notable comment · 2/5Verify in source →
4 JULTHE POMP PODCAST · 05:40
Low pairwise correlation enables safe portfolio leverage
“The guest argued that building a 'Honeycomb' portfolio of 14 non-correlated, high-return-on-equity stocks around gold and timber minimizes volatility, allowing the safe use of leverage to hedge against dollar debasement.”
Core thesis · 5/5Verify in source →
4 JULTHE POMP PODCAST · 06:30
Lindy stocks over concentrated indexes
“The guest argues that investors should replace broad S&P 500 index exposure with Lindy stocks—the oldest, most cycle-tested companies in each sector—to reduce volatility and outperform.”
Substantive discussion · 3/5Verify in source →
4 JULTHE TIM FERRISS SHOW · 00:00
Programmable RNA overcomes genetic medicine's liver limitation
“The bull case for programmable mRNA platforms is their ability to deliver genetic instructions outside the liver to trigger systemic immune responses against metastatic cancers.”
Core thesis · 5/5Verify in source →
The weekly signal

Get a weekly digest of what podcasts said about your watchlist.

Pick a few tickers. Once a week we send the most-discussed ideas across finance podcasts — attributed, with a link to verify. No noise, no advice.

Double opt-in: we’ll email you to confirm before anything else. We store your email and chosen tickers only to send this digest — nothing else, never shared.

Related tickers
NVDAMSFTGOOGLAMZNMETAAAPLMSTRSPYMUTSLACRMCOIN
Browse all tickers →This week’s signal →
MENTIONS & DEPTH REFLECT PODCAST DISCUSSION VOLUME · NOT A RATING, FORECAST, OR RECOMMENDATION